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Abstract  
Objective: Studies have found illness perceptions explain significant variance in health 
outcomes in numerous diseases. However, most of the research is cross-sectional and non-
oncological. We examined, for the first time in breast, colorectal and prostate cancer patients, 
if cognitive and emotional illness perceptions near diagnosis predict future multidimensional 
health-related quality of life (HRQoL).                                                                                                
Methods: UK-based patients (N=334) completed the Illness Perception Questionnaire-
Revised (IPQ-R) within 6 months post-diagnosis and the Quality of Life in Adult Cancer 
Survivors scale 15 months post-diagnosis. Sociodemographic and clinical data were obtained 
from medical records. Hierarchical multiple regression analyses were conducted.                                                
Results: The sociodemographic and clinical factors collectively significantly predicted 8/12 
HRQoL-domains, although for 5/8 accounted for <10% of the variance. For all 12 HRQoL-
domains illness perceptions collectively explained significant substantial additional variance 
(∆R² range: 5.6%–27.9%), and a single IPQ-R dimension was the best individual predictor of 
9/12 HRQoL-domains. The Consequences dimension independently predicted 7/12 HRQoL-
domains; patients who believed their cancer would have a more serious negative impact on 
their life reported poorer future HRQoL. The Emotional Representations and Identity 
dimensions also predicted multiple HRQoL-domains.                                                                                            
Conclusions: Future research should focus on realising the potential of illness perceptions as 
a modifiable target for and mediating mechanism of interventions to improve patients’ 
HRQoL. 
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Background  
In most developed countries survivors of adult cancers form a large and growing group; there 
are 2 million cancer survivors in the UK, and this is estimated to double by 2030 [1]. 
Although many survivors report comparable health-related quality of life (HRQoL) to their 
general population peers, research indicates that a significant number experience on-going 
physical and psychosocial difficulties, including problems with fatigue, sexual functioning, 
emotional wellbeing, work and finances [2-4]. Sociodemographic and clinical factors, such as 
age, socioeconomic status (SES), diagnosis and type of treatment, do not fully account for the 
variance in survivorship HRQoL and wellbeing outcomes [5-7]. Moreover, as these factors 
are largely immutable or not therapeutically modifiable, they are not a feasible target for 
interventions to improve HRQoL.  
One potentially modifiable predictor of HRQoL is a patient’s own personal beliefs 
about their illness and its treatment, and their emotional responses towards it, which are 
known as illness representations or perceptions. Illness perceptions are theorised to affect 
disease adaptation and outcomes within the framework of the common-sense self-regulation 
model (SRM) of illness [8,9]. The SRM posits that, when faced with illness, individuals form 
beliefs about the disease (cognitive representation) and experience an emotional reaction 
(emotional representation), which together affect physical and psychosocial outcomes, 
primarily via influencing coping responses. Theory and research suggest illness cognitions 
are organised around five interrelated dimensions: beliefs about the diagnostic label and 
symptoms associated with the illness, its aetiology, duration, consequences, and 
controllability/curability [10,11]. Quantitative research into illness representations has 
overwhelmingly used the Revised Illness Perception Questionnaire [12] (or its predecessor or 
short-form), which assesses these cognitive dimensions as well as a patient’s emotional 
representation. 
Over the last 15 years, cross-sectional and longitudinal studies in various diseases, 
including diabetes, asthma and myocardial infarction, have found illness representations to 
account for a significant proportion of the variance in a range of illness outcomes, including 
medication adherence, psychological morbidity and HRQoL, even after controlling for 
sociodemographic and disease predictors [11,13]. This suggests that illness representations 
play an important role in patient outcomes, and that interventions to change these 
representations could potentially improve patients’ wellbeing and outcomes. Although 
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the precise pattern of relationships between illness representations and outcomes differs 
somewhat across samples, fairly consistent associations have emerged; for example, 
perceptions of low personal control, low treatment amenability and more negative 
consequences, and more negative emotional feelings about the illness, are generally 
associated with poorer outcomes  [14-16]. More recent studies have extended these findings 
to oncology and shown that illness perceptions are also associated with health and wellbeing 
outcomes in cancer patients [5,17-20]. 
Most oncological illness perceptions research is cross-sectional, leaving the 
temporal direction of links between perceptions and health outcomes indeterminate. 
The few prospective studies that have been conducted, however, indicate that cancer 
patients’ illness perceptions are independently predictive of psychosocial outcomes 3 to 
24 months later, including HRQoL, psychological morbidity and return to work [21-26]. 
We aimed to further explore the value of illness perceptions in predicting HRQoL in cancer 
using data from patients with breast, colorectal and prostate malignancies. To our knowledge, 
none of the prospective illness perception studies with breast cancer patients have assessed 
HRQoL (e.g.[21,24-26], only one predictive study has been conducted with prostate cancer 
patients (and their spouses), and this examined only two illness cognition dimensions [27], 
and no longitudinal studies have been undertaken with colorectal cancer patients. To date, it 
would appear that only studies with head and neck cancer patients have prospectively 
explored the role of cognitive and emotional illness representations in predicting future 
multidimensional HRQoL [22,23].  
This paper aims to explore, for the first time in breast, colorectal and prostate cancer 
patients, the extent to which cognitive and emotional illness perceptions assessed 
prospectively within 6 months of diagnosis, are independently predictive of multidimensional 
HRQoL 15 months post-diagnosis. Specifically, we aim to assess: (1) the amount of variance 
in HRQoL accounted for by sociodemographic and clinical factors, (2) the additional 
variance, over and above these factors, explained by illness perceptions, and (3) which, if 
any, illness perceptions are important predictors across multiple HRQoL-domains.  
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Methods 
This paper presents a secondary analysis, using data from a study with the primary aim 
of feasibility testing a novel e-system for collecting patient reported outcomes online and 
linking them with cancer registry data: the electronic Patient-reported Outcomes from Cancer 
Survivors (ePOCS) system. The study received National Health Service (NHS) ethical 
approval. Comprehensive accounts of the design and development of the ePOCS system 
[28], and the protocol [29] and results [30] of the feasibility study have been published 
open-access and can be consulted for more detailed methodological information (e.g. 
regarding recruitment procedures, the data collection time-points).  
 
Participants  
Patients were recruited by clinicians and research nurses from five NHS hospitals in 
Yorkshire, England. Adult patients were eligible if diagnosed with potentially curable breast, 
colorectal or prostate cancer within the last 6 months, and if English literate.  
 
Measures 
Revised Illness Perception Questionnaire (IPQ-R) [12]   comprises seven core dimensions 
assessing people’s beliefs about: timeline–acute/chronic (illness duration), consequences 
(impact of the illness on their life), personal control (how much influence they have over the 
illness), treatment control (treatability of the illness ), illness coherence (how well they 
understand the illness) and timeline–cyclical (whether the illness trajectory is constant or 
cyclical), as well as emotional representations (emotional impact of the illness). In addition, 
the IPQ-R also assesses beliefs about identity (symptom attribution) and causes (of the 
illness), although the causes dimension was omitted from the ePOCS feasibility study as it 
was felt by patients on the study steering group that it may distress respondents. The core 
dimensions are assessed by 38 items, such as “my cancer is a serious condition”, rated from 1 
(strongly disagree) to 5 (strongly agree), and the identity scale is assessed by 14 symptoms 
(e.g. headaches) rated yes/no according to whether the symptom has been experienced “since 
my cancer” and is “related to my cancer”. Higher scores indicate a stronger illness identity, 
stronger perceptions of illness chronicity, a cyclical timeframe and negative consequences, 
and greater distress; lower scores indicate low perceived personal and treatment control and 
less understanding of the illness (for score ranges, see Table 2). Participants completed the 
IPQ-R within 6 months post-diagnosis. 
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Quality of Life in Adult Cancer Survivors (QLACS) scale [31]   assesses seven generic and 
five cancer-specific HRQoL-domains (see Table 2). Comprehensive information about the 
domains and comprising items is available elsewhere [31,32]. QLACS comprises 47 
items, such as “you felt tired a lot” rated from 1 (never) to 7 (always) with respect to the past 
four weeks. Domain scores range from 4–28, with higher scores indicating more of the 
construct under measure (e.g. more positive feelings, more cognitive problems). QLACS was 
developed for longer-term survivors 5+ years post-diagnosis, although we have shown 
that the scale has similarly good classic psychometric properties among the current 
sample of shorter-term survivors [32]. As our previous psychometric analyses did not, 
however, support the validity of computing a QLACS Generic summary score 
(although did support a Cancer-Specific summary score), we chose here to analyse the 
12 HRQoL-domains individually. Participants completed QLACS 15 months post-
diagnosis (within a 6 week window; 3 weeks either side of the precise 15-month date). 
 
Sociodemographic and clinical information   was obtained from patients’ medical records 
(see Table 1), except self-reported ethnicity. Socioeconomic status (SES) was calculated via 
patients’ postcodes using Index of Multiple Deprivation (IMD) scores and quintiles. IMD 
scores are a Government-produced measure of deprivation for small areas in England 
based on numerous indicators such as educational attainment, housing quality and 
employment and crime rates; for comprehensive information see the GOV.UK website 
[33]. 
 
Measures were administered via the ePOCS system, which is accessible from any internet-
enabled device. Participants were not permitted to skip questions, but had the option to 
indicate they “prefer not to answer”.  
 
Analysis  
Missing IPQ-R and QLACS data were managed following recommendations from the 
scale authors (details available at: [32,34]). Descriptive statistics, t-tests, chi-square tests, 
correlations and Cronbach’s alphas were calculated, using IBM-SPSS version-21, to describe 
and explore the sample characteristics and IPQ-R and QLACS scores. Hierarchical regression 
analyses were conducted, using Stata version-12, to determine the amount of variance in each 
of the QLACS domains accounted for by sociodemographic and clinical factors and the 
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additional variance, over and above these factors, explained by illness perceptions within 6 
months of diagnosis (i.e. change in R-squared: ∆R²). Tables 3 and 4 detail the predictors 
entered into the models at the first and second steps. The standardised regression coefficients 
(β) and t-tests were examined to determine the contribution of individual predictors at each 
step. To compensate for multiple testing, we report regression results at the p≤0.01 
significance level. 
 
Results  
Participants  
Comprehensive information on recruitment and attrition to the ePOCS feasibility study 
has been previously published [30]; of the 636 patients who joined this study, 407 (64.0%) 
completed the QLACS scale, and of these, 334 (82.1%) had complete IPQ-R, 
sociodemographic and clinical data. The characteristics of this final sample are summarised 
in Table 1. The 334 participants included in these analyses are younger (p=0.016), more 
affluent (p=0.004), and more likely to have prostate cancer (p<0.001), than those patients 
who joined the ePOCS study but are not here included (i.e. due to attrition, incomplete data 
etc.). There were no such group-differences by gender (p=0.424) or treatment (all p>0.105). 
There were no IPQ-R differences between participants included in these analyses and those 
who completed some portion of the IPQ-R but are not here included (all p≥0.126, except 
treatment control p=0.058). On average, participants completed the IPQ-R 3.5 months post-
diagnosis (M±SD=110±49 days). A sample size of N=334 is sufficient for the current 
regression analyses with sixteen predictors following the general recommendation that 
10-15 participants are required per predictor [35].   
 
Illness perception and HRQoL scores  
The number of days post-diagnosis participants completed the IPQ-R was unrelated to 
scores for all dimensions (all p≥0.079) save identity, where higher scores were weakly 
related to completion farther out from diagnosis (r=.202, p<0.001). Correlations among 
the IPQ-R dimensions ranged from r=.002 – .570, indicating no multicollinearity [35]. 
As Table 2 shows, on average, participants did not tend to believe their cancer would last a 
long time and had strong beliefs that it was treatable, although also had relatively strong 
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perceptions of negative consequences and feelings of distress. The IPQ-R score ranges were 
large, however, indicating very marked differences in perceptions between some participants. 
The QLACS scores show that many participants were experiencing relatively few problems 
and concerns, although for each domain a small proportion of participants obtained scores 
indicating very low HRQoL. All IPQ-R dimensions and QLACS domains had acceptable 
internal reliability (α≥.70). 
 
Sociodemographic and clinical factors predicting 15-month HRQoL 
The results of the regression analyses are summarised in Tables 3 and 4. For 8/12 QLACS 
domains the overall model comprising step 1 was significant (all p≤0.003); the amount of 
variance accounted for by the sociodemographic and clinical factors collectively ranged from 
5.3% (cognitive problems and pain) to 27.5% (appearance concerns). Gender and treatment 
were not predictive of any of the QLACS domains. Age was a significant predictor of three 
domains, such that older participants reported higher HRQoL. SES was associated with five 
domains, such that one or more quintiles reported higher HRQoL than the most deprived 
quintile. Diagnosis was also a predictor, such that breast patients reported lower HRQoL than 
colorectal (four domains) and prostate (two domains) patients.  
 
Illness perceptions predicting 15-month HRQoL 
As shown in Tables 3 and 4, the inclusion of illness perceptions significantly improved the 
predictive power of the model for all 12 QLACS domains (overall model steps 1 & 2 all 
p≤0.001; ∆R
2 
all p≤0.002). The amount of variance explained by the two-step model ranged 
from 9.4% (sexual problems) to as much as 40.0% (appearance concerns). Illness perceptions 
explained a further 5.6% (sexual problems) to 27.9% (distress over recurrence) of the 
variance, and more than an additional 10% for 10/12 domains. When illness perceptions were 
added to the model, for 9/12 QLACS domains, the strongest predictor of HRQoL was one of 
the IPQ-R dimensions (β range = |0.203–0.451|). For the appearance concerns and benefits 
of cancer domains, although diagnosis was the strongest predictor, an IPQ-R dimension 
was still the second most important predictor; for the sexual problems domain, no 
individual predictor was significant at the p≤0.01 level. To conserve space, the β 
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coefficients for the step 1 predictors when included in the two-step model are not shown in 
Tables 3 & 4. 
The consequences IPQ-R dimension predicted 5/7 generic and 2/5 cancer-specific 
QLACS domains (β range = |0.180–0.278|), and independently accounted for between 3.8% 
(social avoidance) and 1.5% (positive feelings) of the variance in HRQoL. Patients who 
believed within 6 months post-diagnosis that their cancer would have more serious negative 
consequences on their life reported lower 15-month HRQoL. The emotional representations 
and identity dimensions were also predictive of multiple QLACS domains (β range = 
|0.198–0.451). Patients who felt more negative about their cancer and attributed more 
symptoms to their cancer reported lower 15-month HRQoL (except for a positive relationship 
between identity and perceived benefits of cancer). 
 
Discussion  
For all HRQoL-domains illness perceptions explained significant additional variance over 
and above that accounted for by the sociodemographic and clinical factors, and for 9/12 
domains a single IPQ-R dimension was the best individual predictor. These findings are 
consistent with the SRM [8,9] and previous prospective non-cancer studies (e.g.[16,36]). To 
date, only studies with head and neck cancer patients have prospectively explored the role of 
cognitive and emotional illness representations in predicting multidimensional HRQoL 
[22,23]; the current study corroborates the findings from these studies and extends them to 
cancer patients from the largest UK diagnostic and survivor groups. Our findings underline 
the predictive value of patients’ illness perceptions, even over a relatively long time period.  
The consequences dimension predicted 7/12 HRQoL-domains. Consistent with 
previous research [14-18], patients’ who thought their cancer would have more serious 
negative consequences for their relationships, finances etc. reported poorer future HRQoL. 
Consequences has emerged as a predictor of multiple outcomes and/or one of the strongest 
IPQ-R predictors in several previous cancer (e.g.[5,17,23]) and non-cancer (e.g.[15,16,36]) 
studies. Emotional representations predicted 4/12 HRQoL-domains, perhaps 
unsurprisingly: negative and positive feelings and recurrence and family-related 
distress. The identity dimension also predicted 4/12 HRQoL-domains. Consistent with 
other studies [15-18], greater distress and a stronger illness identity were generally 
predictive of lower HRQoL. These findings suggest that, especially where time or 
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resources are limited, illness perception-based interventions should focus foremost on 
addressing cancer patients’ perceptions of catastrophic sequelae, and also give 
prominence to emotional distress and symptom attribution. However, not all cancer 
studies have found consequences to be an especially important predictor (e.g.[20,22,26]), and 
even in this study consequences alone explained just 2%–4% of the variance in the HRQoL-
domains. Substantial additional variance was explained by the IPQ-R dimensions as a 
collective profile.  
In a recent review on mechanisms of effect in psychosocial interventions for adults 
with cancer, Stanton et al. [37] concluded that “promising classes of mediators include 
alterations in cognitions (i.e. expectancies, illness representations)” (p.318). Growing 
evidence in several illnesses indicates that various interventions can be effective in modifying 
maladaptive illness beliefs, and improving patients’ illness-related behaviours and outcomes 
(e.g.[38,39]). However, the potential of illness perceptions as a change-target to improve 
HRQoL is yet to be fully explored or realised, particularly in cancer. Although recent 
research has shown how illness perceptions relate to personality characteristics such as Type 
D [40] and to the illness perceptions of significant others [27], there is a lack of knowledge 
about how and why particular perceptions develop. There is also insufficient understanding 
about the mechanisms underlying changes in illness perceptions and subsequent 
improvements in outcomes. Although illness perceptions are theorised to impact outcomes 
primarily via influencing coping responses [8,9], few intervention studies have assessed this. 
Future research should address these knowledge gaps to facilitate the development of 
illness perception-based interventions.  
The strengths of this study are its relatively large multi-diagnostic sample, longer-
term follow-up and multidimensional assessment of HRQoL. Although the prospective 
findings are consistent with, they do not confirm, causation; there are numerous 
unmeasured variables which may, to varying degrees, account for the relationships 
between illness perceptions and HRQoL (e.g. symptom burden, performance status). A 
limitation of this study is the lack of a ‘baseline’ measure of HRQoL, which means we 
may have overestimated to some degree the predictive power of the illness perceptions 
dimensions. However, it would not have been appropriate to administer the survivor-
specific QLACS scale within 6 months post-diagnosis (the first time-point in the ePOCS 
study [30]). Not all prospective illness perceptions studies are able to include baseline 
outcome measures [19,24]. Another key limitation is that participants were being treated 
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with curative intent, and it is likely that those who joined and stayed in the study were 
healthier than those who declined or withdrew. However, any range restriction in HRQoL 
scores could arguably have served to underestimate the predictive power of illness 
perceptions [16,36].  
This paper shows, for the first time in breast, colorectal and prostate cancer patients, 
that cognitive and emotional illness perceptions within 6 months post-diagnosis were an 
independent predictor of 15-month HRQoL.  
 
The ePOCS study was funded by Macmillan Cancer Support. Conflicts of Interest: none 
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Table 1. Sample characteristics (N=334) 
 
  
    Male 149(44.6%) 
    Female     185(55.4%) 
  
Age  years, M±SD (range) 60.24±10.40 (24–84) 
  
Socioeconomic status   
    1 (most deprived quintile) 47(14.1%) 
    2 60(18.0%) 
    3 54(16.2%) 
    4 92(27.5%) 
    5 (least deprived quintile) 81(24.3%) 
  
    Caucasian 333(99.7%) 
    Non-Caucasian   1(0.3%) 0 
  
Cancer diagnosis   
    Breast 156(46.7%) 
    Colorectal 83(24.9%) 
    Prostate  95(28.4%) 
  
Treatment up to 15 months 
post-diagnosis (yes/no) 
 
    Surgery  214(64.1%) 
    Chemotherapy  108(32.3%) 
    Radiotherapy  122(36.5%) 
    Hormone treatment  68(20.4%) 
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Table 2. Descriptive statistics and Cronbach’s alphas for the IPQ-R dimensions and QLACS domains  
 
IPQ-R dimension 
(score range) 
n Mean±SD Min – Max 
 
Alpha (α) 
 
Identity 
(0 – 14) 
334 3.24±2.98 0 – 12 n/a 
Timeline – acute/chronic 
(6 – 30) 
334 13.80±5.01 6 – 30 .90 
Consequences 
(6 – 30) 
334 19.30±5.04 6 – 30 .83 
Personal control  
(6 – 30) 
334 20.06±4.22 6 – 30 .81 
Treatment control  
(5 – 25) 
334 20.79±2.78 10 – 25 .82 
Illness coherence 
(5 – 25) 
334 18.58±3.94 7 – 25 .87 
Timeline – cyclical  
(4 – 20) 
334 9.93±2.94 4 – 17 .77 
Emotional representations 
(6 – 30)  
334 18.16±5.25 6 – 30 
 
.89 
 
    
QLACS domain 
(score range = 4 – 28) 
    
Generic      
Negative feelings  334 9.83±4.71 4 – 28 .89 
Positive feelings 334 21.08±5.81 4 – 28 .94 
Cognitive problems (with 
attention and memory)  
334 9.37±4.44 4 – 27 .87 
Sexual problems  283 12.83±6.32 4 – 28 .77 
Pain 333 9.29±5.19 4 – 26 .90 
Fatigue 334 12.17±5.34 4 – 28 .90 
Social avoidance (e.g. of 
friends, gatherings) 
332 7.49±4.40 4 – 26 .84 
Cancer-specific      
Appearance concerns  334 8.07±5.70 4 – 28 .85 
Financial problems 328 6.70±4.53 4 – 28 .75 
Distress over recurrence 333 11.72±6.02 4 – 28 .90 
Family-related distress (worry 
family are at risk of cancer) 
333 9.51±5.76 4 – 28 .88 
Benefits of cancer (e.g. better 
coping skills) 
330 16.11±6.50 4 – 28 .87 
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Table 3. Summary of the regression analyses for the generic QLACS domains 
 
Negative 
feelings 
Positive feelings 
Cognitive 
problems 
Sexual problems Pain Fatigue 
Social avoidance 
 
 Fdf, Total adj R²  Fdf, Total adj R²  Fdf, Total adj R²  Fdf, Total adj R²  Fdf, Total adj R²  Fdf, Total adj R²  Fdf, Total adj R²  
Step 1 3.2312,321, 0.075*** 1.7912,321, 0.028 2.5412,321, 0.053** 1.9212,270, 0.038 2.5512,320, 0.053** 3.8212,321, 0.092*** 3.1812,319, 0.073*** 
Step 2 6.8820,313, 0.261*** 5.3520,313, 0.207*** 3.9320,313, 0.149*** 2.4720,262, 0.094*** 5.8120,312, 0.225*** 6.5220,313, 0.249*** 5.5920,311, 0.217*** 
        
 ∆R² (%) ∆R² (%) ∆R² (%) ∆R² (%) ∆R² (%) ∆R² (%) ∆R² (%) 
 0.186 (18.6%)*** 0.179 (17.9%)*** 0.096 (9.6%)*** 0.056 (5.6%)** 0.172 (17.2%)*** 0.157 (15.7%)*** 0.144 (14.4%)*** 
        
Step 1  β(SE) β(SE) β(SE) β(SE) β(SE) β(SE) β(SE) 
Gender  -0.059(1.036) -0.080(1.309) -0.068(0.988) 0.106(1.612) 0.030(1.155) 0.048(1.164) 0.092(0.967) 
Age  -0.155(0.028) 0.054(0.035) -0.114(0.027) -0.123(0.043) 0.065(0.031) 0.082(0.031) -0.115(0.026) 
SES: IMD quintile 1 v 2 -0.055(0.907) 0.055(1.145) -0.016(0.865) -0.047(1.357) -0.093(1.010) -0.167(1.018) -0.200(0.851)** 
SES: IMD quintile 1 v 3 -0.146(0.931) 0.123(1.176) -0.051(0.888) -0.115(1.372) -0.175(1.044) -0.223(1.046)** -0.248(0.869)*** 
SES: IMD quintile 1 v 4 -0.202(0.840) 0.181(1.060) -0.149(0.801) -0.042(1.251) -0.279(0.936)*** -0.340(0.943)*** -0.329(0.784)*** 
SES: IMD quintile 1 v 5 -0.144(0.854) 0.182(1.078) -0.090(0.814) -0.103(1.269) -0.191(0.951) -0.280(0.959)*** -0.313(0.797)*** 
Diagnosis: breast v colorectal -0.151(0.965) 0.187(1.218) -0.125(0.920) -0.100(1.479) -0.249(1.075)** -0.240(1.083)** -0.242(0.904)** 
Diagnosis: breast v prostate -0.112(1.344) 0.231(1.697) -0.078(1.281) 0.094(1.991) -0.322(1.497) -0.360(1.509)** -0.212(1.257) 
Treatment: surgery  0.009(0.677) 0.045(0.855) 0.047(0.645) -0.050(0.988) -0.017(0.754) -0.023(0.760) -0.028(0.632) 
Treatment: chemotherapy  -0.023(0.683) 0.025(0.863) -0.034(0.652) -0.017(1.024) -0.094(0.761) -0.001(0.767) -0.100(0.641) 
Treatment: radiotherapy  0.025(0.576) 0.014(0.727) -0.021(0.549) 0.098(0.858) 0.002(0.644) 0.036(0.647) 0.012(0.539) 
Treatment: hormone treatment   -0.055(0.809) -0.034(1.021) 0.029(0.771) 0.019(1.222) -0.112(0.905) -0.100(0.908) -0.073(0.757) 
        
Step 2  β(SE) β(SE) β(SE) β(SE) β(SE) β(SE) β(SE) 
Identity -0.037(0.103) -0.002(0.132) 0.001(0.104) 0.070(0.170) 0.235(0.117)*** 0.106(0.118) 0.065(0.100) 
Timeline–acute/chronic -0.085(0.065) 0.021(0.083)  -0.068(0.065) 0.063(0.104) 0.044(0.073) 0.020(0.074) -0.032(0.062) 
Consequences 0.207(0.063)** -0.180(0.080)** 0.271(0.064)*** 0.190(0.105) 0.170(0.071) 0.241(0.072)*** 0.278(0.060)*** 
Personal control -0.081(0.060) 0.079(0.077) -0.158(0.061)** 0.014(0.100) 0.008(0.068) -0.049(0.069) -0.004(0.058) 
Treatment control  -0.076(0.111) 0.168(0.142) 0.036(0.113) 0.048(0.176) -0.080(0.126) -0.019(0.127) -0.143(0.107) 
Illness coherence -0.045(0.067) 0.097(0.085) 0.006(0.067) 0.044(0.105) -0.070(0.075) -0.113(0.076) -0.086(0.064) 
Timeline–cyclical  0.120(0.100) 0.016(0.128) 0.158(0.102) 0.097(0.161) 0.121(0.113) 0.137(0.115) -0.041(0.096) 
Emotional representations  0.258(0.056)*** -0.203(0.072)** 0.020(0.057) 0.065(0.089) -0.002(0.063) 0.006(0.064) 0.112(0.054) 
**p≤0.01; ***p≤0.001; adj=adjusted; SE=standard error 
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Table 4. Summary of the regression analyses for the cancer-specific QLACS domains 
 
Appearance 
concerns  
Financial problems 
Distress over 
recurrence  
Family-related 
distress  
Benefits of cancer 
 Fdf, Total adj R²  Fdf, Total adj R²  Fdf, Total adj R²  Fdf, Total adj R²  Fdf, Total adj R²  
Step 1 11.5512,321, 0.275*** 4.3112,315, 0.108*** 4.2512,320, 0.105*** 1.3812,320, 0.014 1.3112, 317, 0.011 
Step 2 12.1220,313, 0.400*** 5.5020,307, 0.216*** 11.3420,312, 0.384*** 3.2520,312, 0.119*** 3.3320,309, 0.124*** 
      
 ∆R² (%) ∆R² (%) ∆R² (%) ∆R² (%) ∆R² (%) 
 0.125 (12.5%)*** 0.108 (10.8%)*** 0.279 (27.9%)*** 0.105 (10.5%)*** 0.113 (11.3%)*** 
      
Step 1  β(SE) β(SE) β(SE) β(SE) β(SE) 
Gender  0.009(1.110) 0.089(1.002) -0.069(1.302) -0.177(1.309) -0.266(1.491) 
Age  -0.331(0.030)*** -0.304(0.027)*** -0.223(0.035)*** -0.125(0.035) -0.065(0.040) 
SES: IMD quintile 1 v 2 -0.083(0.971) -0.096(0.871) 0.010(1.144) -0.038(1.150) -0.133(1.303) 
SES: IMD quintile 1 v 3 -0.156(0.997) -0.190(0.897)** -0.033(1.170) -0.103(1.176) -0.080(1.329) 
SES: IMD quintile 1 v 4 -0.183(0.899)** -0.205(0.806) -0.131(1.055) -0.158(1.060) -0.096(1.200) 
SES: IMD quintile 1 v 5 -0.118(0.914) -0.180(0.818) -0.061(1.072) -0.118(1.078) -0.100(1.219) 
Diagnosis: breast v colorectal -0.269(1.033)*** -0.095(0.937) -0.098(1.212) 0.129(1.218) 0.174(1.394) 
Diagnosis: breast v prostate -0.365(1.439)*** -0.163(1.297) -0.110(1.688) 0.146(1.697) 0.333(1.924) 
Treatment: surgery  -0.067(0.725) 0.035(0.640) -0.010(0.850) 0.005(0.855) 0.139(0.972) 
Treatment: chemotherapy  -0.050(0.732) -0.084(0.652) 0.016(0.858) -0.022(0.863) 0.012(0.980) 
Treatment: radiotherapy  -0.074(0.617) 0.022(0.547) 0.043(0.724) 0.010(0.727) 0.062(0.828) 
Treatment: hormone treatment   -0.115(0.866) -0.098(0.770) -0.004(1.017) 0.055(1.023) 0.022(1.157) 
      
Step 2  β(SE) β(SE) β(SE) β(SE) β(SE) 
Identity 0.095(0.113) 0.064(0.104) 0.198(0.120)*** 0.204(0.138)** 0.255(0.155)*** 
Timeline–acute/chronic -0.011(0.070) 0.097(0.064)  0.054(0.076) -0.004(0.087) 0.152(0.098) 
Consequences 0.220(0.069)*** 0.229(0.063)*** 0.025(0.073) -0.050(0.084) -0.111(0.095) 
Personal control -0.027(0.065) -0.026(0.060) -0.114(0.070) 0.014(0.080) 0.091(0.090) 
Treatment control  0.058(0.121) 0.098(0.111) 0.009(0.130) 0.070(0.149) 0.266(0.168)*** 
Illness coherence -0.097(0.073) -0.113(0.067) -0.016(0.078) -0.110(0.089) 0.111(0.100) 
Timeline–cyclical  0.064(0.109) 0.126(0.100) -0.004(0.117) 0.048(0.134) 0.060(0.151) 
Emotional representations  0.128(0.061) -0.028(0.056) 0.451(0.065)*** 0.248(0.075)*** 0.072(0.085) 
**p≤0.01; ***p≤0.001; adj=adjusted; SE=standard error 
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